<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03708939</url>
  </required_header>
  <id_info>
    <org_study_id>170-2</org_study_id>
    <nct_id>NCT03708939</nct_id>
  </id_info>
  <brief_title>Microbiome and Non-caloric Sweeteners in Humans</brief_title>
  <official_title>The Role of the Microbiome in Personalized Human Response to Non-caloric Sweeteners</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weizmann Institute of Science</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weizmann Institute of Science</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-caloric sweeteners are common food supplements consumed by millions worldwide as means of&#xD;
      combating weight gain and diabetes, by retaining sweet taste without increasing caloric&#xD;
      intake. While they are considered safe, there is increasing debate regarding their potential&#xD;
      role in contributing to metabolic derangements in some humans. The investigators recently&#xD;
      demonstrated that non-caloric sweeteners consumption could induce glucose intolerance in mice&#xD;
      and, in preliminary experiments, in distinct human subsets, by functionally altering the gut&#xD;
      microbiome, and that the gut microbiome plays an important role in mediating differential&#xD;
      glucose responses to identical foods. The proportion of the human population that is&#xD;
      susceptible to glucose intolerance induced by non-caloric sweeteners, the common factors that&#xD;
      are shared between these individuals and whether and how the microbiome promotes the&#xD;
      metabolic derangements remain to be addressed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 19, 2017</start_date>
  <completion_date type="Actual">January 1, 2021</completion_date>
  <primary_completion_date type="Actual">August 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood glucose level</measure>
    <time_frame>28 days</time_frame>
    <description>Continuous glucose monitor device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiome</measure>
    <time_frame>28 days</time_frame>
    <description>Stool and oral samples</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Glucose Intolerance</condition>
  <condition>Glucose, Low Blood</condition>
  <condition>Glucose, High Blood</condition>
  <arm_group>
    <arm_group_label>glucose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>aspartame</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sucralose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>saccharin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stevia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No supplement control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glucose</intervention_name>
    <description>Daily consumption of 5g of glucose, for 14 days.</description>
    <arm_group_label>glucose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Aspartame</intervention_name>
    <description>Daily consumption of six commercially available sachets containing aspartame and glucose as bulking agent (1g each sachet), for 14 days.</description>
    <arm_group_label>aspartame</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sucralose</intervention_name>
    <description>Daily consumption of six commercially available sachets containing sucralose and glucose as bulking agent (1g each sachet), for 14 days.</description>
    <arm_group_label>sucralose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Saccharin</intervention_name>
    <description>Daily consumption of six commercially available sachets containing saccharine and glucose as bulking agent (1g each sachet), for 14 days.</description>
    <arm_group_label>saccharin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Stevia</intervention_name>
    <description>Daily consumption of six commercially available sachets containing Stevia and glucose as bulking agent (1g each sachet), for 14 days.</description>
    <arm_group_label>Stevia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Supplement</intervention_name>
    <description>Follow up without any dietary supplementation.</description>
    <arm_group_label>No supplement control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. BMI&lt;28&#xD;
&#xD;
          2. Age - 18-70&#xD;
&#xD;
          3. Capable of working with smartphone application&#xD;
&#xD;
          4. Capable to work with a glucometer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Consumption of antibitioics 3 months prior to the first day of the experiment.&#xD;
&#xD;
          2. Consumption of Non caloric sweetners 6 months prior to the first day of the&#xD;
             experiment.&#xD;
&#xD;
          3. Diagnosis with type 1 or type 2 diabetes.&#xD;
&#xD;
          4. Pregnancy, fertility treatments&#xD;
&#xD;
          5. Breastfeeding (Including baby to breast and bottle feeding expressed breast milk)&#xD;
&#xD;
          6. Chronic disease (e.g. AIDS, Cushing syndrome, CKD, acromegaly, hyperthyroidism etc.)&#xD;
&#xD;
          7. Cancer and recent anticancer treatment&#xD;
&#xD;
          8. Psychiatric disorders&#xD;
&#xD;
          9. Coagulation disorders&#xD;
&#xD;
         10. IBD (inflammatory bowel diseases)&#xD;
&#xD;
         11. Bariatric surgery&#xD;
&#xD;
         12. Alcohol or substance abuse&#xD;
&#xD;
         13. BMI&gt;28&#xD;
&#xD;
         14. Aspartame group only: phenylketonuria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eran Elinav</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weizmann Institute of Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weizmann Institute of Science</name>
      <address>
        <city>Reáº–ovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 14, 2018</study_first_submitted>
  <study_first_submitted_qc>October 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Weizmann Institute of Science</investigator_affiliation>
    <investigator_full_name>Eran Elinav</investigator_full_name>
    <investigator_title>Prof. Eran Elinav</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

